502 related articles for article (PubMed ID: 30910249)
1. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
2. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
4. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
6. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
7. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
[TBL] [Abstract][Full Text] [Related]
8. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
10. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
11. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
12. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.
Imboden S; Tapia C; Scheiwiller N; Kocbek V; Altermatt HJ; Janzen J; Mueller MD; McKinnon B
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):196-203. PubMed ID: 31562818
[TBL] [Abstract][Full Text] [Related]
13. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
14. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
[TBL] [Abstract][Full Text] [Related]
15. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
16. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
17. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
Costigan DC; Dong F; Nucci MR; Howitt BE
Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]